HansBiomed Corporation (KOSDAQ:042520)

South Korea flag South Korea · Delayed Price · Currency is KRW
50,400
-100 (-0.20%)
At close: Feb 27, 2026
519.93%
Market Cap 691.59B
Revenue (ttm) 100.17B
Net Income (ttm) -27.44B
Shares Out 13.72M
EPS (ttm) -2,098.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 223,483
Average Volume 388,175
Open 51,000
Previous Close 50,500
Day's Range 49,550 - 52,100
52-Week Range 6,180 - 54,100
Beta 2.31
RSI 68.73
Earnings Date Feb 12, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 277
Stock Exchange KOSDAQ
Ticker Symbol 042520
Full Company Profile

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Financial Statements

News

There is no news available yet.